# A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

Source: https://onco.cc/trials/nct06253130/  
OnCo record `nct06253130` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of IMP1734 in advanced solid tumours, run by Eikon Therapeutics, now recruiting.

## Summary

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06253130 by Eikon Therapeutics, with 156 participants planned, started 2023-12-11 and due to reach its primary completion in 2027-06-01. Interventions recorded: IMP1734.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06253130
- Phase: 1/2
- Setting: A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors
- Sponsor: Eikon Therapeutics
- Enrolled: 156

## Sources

- ClinicalTrials.gov NCT06253130: https://clinicaltrials.gov/study/NCT06253130

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Eikon Therapeutics](https://onco.cc/companies/eikon-therapeutics/), [IMPACT Therapeutics](https://onco.cc/companies/impact-therapeutics/)
- drugs: [IMP1734](https://onco.cc/drugs/imp1734/)

---
JSON: https://onco.cc/api/v1/entities/nct06253130.json